Regulation of liver fibrosis by matrix metalloproteinase/tissue inhibitor of metalloproteinase and research advances in related therapeutic drugs
10.3969/j.issn.1001-5256.2022.06.042
- VernacularTitle:基质金属蛋白酶/基质金属蛋白酶水解酶对肝纤维化的调控及相关治疗药物研究进展
- Author:
Qian HUANG
1
;
Yan YANG
2
;
Rui ZENG
2
;
Menglin YAO
2
;
Qin SUN
2
,
3
Author Information
1. School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China
2. School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China
3. Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, China
- Publication Type:Reviews
- Keywords:
Liver Cirrhosis;
Matrix Metalloproteinases;
Tissue Inhibitor of Metalloproteinases
- From:
Journal of Clinical Hepatology
2022;38(6):1420-1425
- CountryChina
- Language:Chinese
-
Abstract:
Liver fibrosis is the common consequence of various chronic liver injuries and is mainly characterized by the imbalance between the production and degradation of extracellular matrix, which leads to the accumulation of interstitial collagen and other matrix components. Matrix metalloproteinases (MMPs) and their specific inhibitors, i.e., tissue inhibitors of metalloproteinases (TIMPs), play a crucial role in collagen synthesis and lysis. Through a literature review, this article reviews the experimental studies of liver fibrosis based on MMPs/TIMPs, summarizes the components that may exert an anti-liver fibrosis effect by affecting the expression or activity of MMPs/TIMPs, and attempts to clarify the mechanism of MMPs/TIMPs in regulating collagen homeostasis, so as to provide support for the development of anti-liver fibrosis drugs.
